The purpose of this Phase II trial is to see if R3R01 is safe in patients with Alport Syndrome and Focal Segmental Glomerulosclerosis. This will be done by evaluating how efficient R3R01 is in decreasing proteinuria levels. The study will consists of a screening period, a treatment period, and a follow-up period. If you qualify, you will receive the study drug R3R01 for 12 weeks. We will then follow up with you after for an additional 12 weeks.
1. Age 12 years or older
2. Diagnosis of Alport Syndrome (confirmed by genetic testing and/or kidney biopsy) / Primary FSGS (confirmed by renal biopsy)
1. Uncontrolled diabetes mellitus or hypertension
2. History of organ transplant or possibility of transplant in the six months after screening
If you aren't sure if you qualify, please call us and we will help determine your eligibility.
If you qualify, you will receive R3R01 for 12 weeks. We will then follow up with you for an additional 12 weeks following completion of the study drug treatment.